Zacks Investment Research downgraded Agenus Inc (NASDAQ:AGEN) to Hold in a statement released earlier today.
- Updated: September 28, 2016
Zacks Investment Research has downgraded Agenus Inc (NASDAQ:AGEN) to Hold in a statement released on 09/28/2016.
On 7/29/2016, Jefferies & Co released a statement about Agenus Inc (NASDAQ:AGEN) upped the target price from $6.00 to $7.00 that suggested an upside of 0.26%.
Having a price of $7.07, Agenus Inc (NASDAQ:AGEN) traded -1.11% lower on the day. With the last stock price up 49.34% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. AGEN has recorded a 50-day average of $6.36 and a two hundred day average of $4.77. Trade Volume was down over the average, with 970,180 shares of AGEN changing hands under the typical 1,149,930
Recent Performance Chart
Agenus Inc has with a one year low of $2.61 and a one year high of $7.31 and has a market capitalization of $0.
A total of 5 brokerages have released a report on Agenus Inc. Three brokerages rating the company a strong buy, two brokerages rating the company a buy, one brokerage rating the company a hold, zero brokerages rating the company a underperform, and finally zero brokerages rating the company a sell with a 12-month price target of $10.80.
General Company Details For Agenus Inc (NASDAQ:AGEN)
Agenus Inc. (Agenus) is an immuno-oncology company. The Company is engaged in discovering and developing treatments for patients with cancer. Its approaches are driven by platforms and programs, which include antibody discovery platform, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage and AutoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon). The Company has a portfolio of programs in various stages of development, including a series of antibodies in discovery and pre-clinical and clinical development, Prophage vaccine, a Heat Shock Protein (HSP)-based vaccine candidate for a form of brain cancer that has completed Phase II trials, and a number of QS-21 Stimulon-containing vaccine candidates in late stage development.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.